AzTrials
AzTrials

EpilepsyReCaPABLENCT05934786

Rehabilitation of Cognition and Psychosocial Well-being in Epilepsy

A study testing Cognitive rehabilitation in people with Epilepsy, run by Vilnius University at 1 site in Lithuania.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Epilepsy is a complex and chronic neurological disorder whose definition is not limited to seizures and also includes social, psychological, and cognitive consequences associated with this frequent condition. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Epilepsy
What is being tested?
Cognitive rehabilitation
Could I receive a placebo?
No, everyone receives an active treatment
How many people
70 participants
Where
1 siteLithuania
Study dates
11 Oct 2023to Nov 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Active epilepsy (medication for epilepsy and/or had at least one seizure in the past year)
  • Adults (>17 years)
  • Lithuanian speaker
  • No intellectual disability

Who cannot join

  • Sensory or motor deficit preventing task completion
  • Epilepsy surgery planned during the project
  • Active non-paroxysmal comorbid disorder of the central nervous system (e.g.,
  • neurodegeneration, multiple sclerosis)
  • Active psychiatric disorder during the past year
  • Psychoactive substance use (except social alcohol, tobacco and caffeine use)

Trial locations and contacts

1 site in 1 country.

Lithuania1 site
  • Vilnius University Hospital Santaros Klinikos

    Vilnius

Other trials in Lithuania

About this study

Official title: Rehabilitation of Cognition and Psychosocial Well-being - A Better Life With Epilepsy

Epilepsy is a complex and chronic neurological disorder whose definition is not limited to seizures and also includes social, psychological, and cognitive consequences associated with this frequent condition. Despite good knowledge of the burden of cognitive deficits and psychosocial difficulties in epilepsy, there have been few attempts to address these issues through rehabilitation programs. The Rehabilitation of Cognition and Psychosocial well-being - A Better Life with Epilepsy (ReCaP-ABLE) study will consist of the creation and implementation of a psychological intervention in a randomized waitlist-controlled trial within a sample of adults with epilepsy. The trial is designed to provide novel evidence regarding 1) the effectiveness of a psychological-cognitive intervention in improving quality of life, objective and subjective cognitive functioning as well as reducing mental health symptomatology, 2) the target epilepsy population for which cognitive and psychosocial rehabilitation is most effective, and 3) the transfer effects of such an intervention. This interdisciplinary trial involving neurology and psychology specialists is set to guide evidence-based treatment for cognitive and psychological comorbidities that are prevalent in epilepsy but receive insufficient attention in clinical settings.

Read the detailed description

The aim of the current project is to conduct a randomized waitlist-controlled trial of an original CoRE program, assess its overall efficacity and determine factors associated with a better response to this intervention.

Work schedule Objective 1: To prepare for the study before patient enrolment (2023-04-01 to 2023-12-31, 9 months) Task 1.1. Acquisition of ethical approval according to local regulations, preparation of infrastructure (e.g., reservation of dedicated examination rooms), and personnel. The required infrastructure for clinical examination and evaluation (e.g., electroencephalography, examination rooms) will be available within the clinical center of Vilnius University Hospital Santaros Klinikos while the infrastructure for the conduct of the intervention will be available at the Counseling and training center of the Faculty of Philosophy at Vilnius University. Vilnius University will also provide access to the data management software "MIDAS" and the statistical package for data analysis (SPSS).

Task 1.2. Development of experimental testing material and intervention. This subtask will be accomplished through meetings between investigators in clinical neurology and psychology. Experimental testing material will be developed after conducting a literature review and discussing the tests' feasibility (e.g., duration, mode of application, result analysis).

Task 1.3. Preparation of the study protocol for publication (expected acceptance before patient enrolment) Objective 2: To start patient enrolment and baseline evaluation (2024-01-01 to 2024-02-31, 2 months) and proceed with continuous enrolment, evaluation, intervention, and follow-up (2024-03-01 to 2024-11-30, 9 months).

Task 2.1. Patient recruitment and baseline evaluation Patients will be recruited by neurologists and explained the purpose and workflow of the trial.

The sample size was calculated for a between-group interaction of a two-way repeated measures analysis of variance (ANOVA) with f=0.40, α=0.05, β=0.95, two groups (early and late intervention), three measurement points, 0.5 correlation between repeated measures and no adjustment for non-sphericity. The resulting sample size of n=58 (G*Power 3.1.9.7) was increased by 20% to n=70 to account for dropouts and corresponded well to the mean sample size and attrition rates in previous trials (Joplin et al., 2018).

Inclusion criteria:

Active epilepsy (medication for epilepsy and/or had at least one seizure in the past year) Adults (>17 years) Lithuanian speaker No intellectual disability

Exclusion criteria:

Sensory or motor deficit preventing task completion Epilepsy surgery planned during the project Active non-paroxysmal comorbid disorder of the central nervous system (e.g., neurodegeneration, multiple sclerosis) Active psychiatric disorder during the past year Psychoactive substance use (except social alcohol, tobacco, and caffeine use)

Components of the baseline evaluation:

Demographic and socioeconomic characteristics (case report form) Clinical characteristics (e.g., seizure frequency, type and duration of epilepsy, medication use, comorbidities, previous exposure to psychological counseling), case report form.

Epilepsy re-evaluation by the neurologist (including electroencephalography) Questionnaire data (scales used): quality of life (QOLIE-31-P), anxiety (GAD-7), depression (NDDI-E), suicidality (Columbia Suicide Severity Rating Scale), metacognition (MCQ-30), Jacoby's 3-item Stigma Scale, antiseizure drug adverse effects (LAEP), the Short Form (36) Health Survey, subjective evaluation of cognitive functions (ad hoc Likert scales 0 to 10).

Objective neuropsychological assessment, up to one hour per examination (indicated examples may be substituted by equivalent tests):

Reaction speed (e.g., Trail Making Tests A and B) Working memory (e.g., Digit Span Test) Verbal fluency (e.g., categorical, phonemic naming) Short-term and long-term memory: verbal (short story or word list) and visuospatial (complex figure) at three delays (e.g., immediate, 30 min, and 4 weeks) to test for accelerated forgetting.

Experimental memory tasks with high everyday significance (e.g., map learning, appointment memory, close autobiographical memory) Task 2.2. The intervention (2024-03-01 to 2024-11-31 (early intervention group) and 2025-06-01 to 2026-03-31 (late intervention group)) Patient randomization will be done using dedicated software (e.g., https://www.randomizer.org/). The investigators performing questionnaire-based and neuropsychological assessment will be blinded from the status of the patient.

The intervention is planned to consist of six individual one-hour therapy sessions with certified psychologists followed by two group sessions (a total of two months per patient). The intervention will consist of all parts of the Strategies-Outsourcing-Social support toolbox (Baxendale, 2020) and include psychoeducation, lifestyle issues, coping strategies and homework. It will be developed after group meetings and all psychologists will be trained by a leading specialist to ensure standardization.

Task 2.3. End of patient recruitment and intervention, last follow-up investigations (2024-12-01 to 2025-03-31, 4 months) Objective 3: To conduct data analysis and disseminate the results (2025-04-01 to 2026-03-31, 12 months) Task 3.1 Data analysis, drafting, and editing of the final report, publication, and presentation of the study results (2025-04-01 to 2026-03-31, 12 months).

The efficacy of the intervention will be defined as a significant improvement in one of the primary outcomes (quality of life or verbal memory), tested with a repeated measure between factors AN(C)OVA. Dynamic changes of other outcome measures will be tested respectively. The association between demographic and clinical variables with study endpoints will be conducted by means of linear and ordinal regression modeling. Open-access publishing of the study results will be sought.

Intervention is simultaneously done for the late intervention group, which is treated as a waitlist control during data analysis (see Task 2.2).

Conditions
Epilepsy
Being tested
Cognitive rehabilitation
Keywords
Epilepsy, neuropsychology, memory, cognitive functions, quality of life, mental health, rehabilitation
Medical subject headings
Epilepsy, Psychological Well-Being

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cognitive rehabilitationBehavioural

    Six individual one-hour therapy sessions with certified psychologists followed by two group sessions (a total of two months per patient). The intervention will consist of all parts of the Strategies-Outsourcing-Social support toolbox (Baxendale, 2020) and include psychoeducation, lifestyle issues, coping strategies and homework.

Study groups in NCT05934786
Study groupRoleWhat they receive
Early intervention groupActive comparatorThe intervention is planned to consist of six individual one-hour therapy sessions with certified psychologists followed by two group sessions (a total of two months (8 weeks) per patient).
Receives: Behavioral: Cognitive rehabilitation
late intervention groupActive comparatorFor 8 weeks this group will receive the usual treatment, then, after repeated cognitive evaluation, will receive the same intervention: six individual one-hour therapy sessions with certified psychologists followed by two group sessions (a total of two months per patient).
Receives: Behavioral: Cognitive rehabilitation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Quality of life index

    QOLIE-31-P will be used before and after interventions. The efficacy of the intervention will be defined as a change from baseline value immediately before intervention at 8 weeks immediately after intervention

    Measured: Immediately before intervention and after.

  2. Delayed verbal recall

    The short story and word list will be used immediately before the intervention, repeated after 30 minutes and immediately after intervention after 4 weeks. The efficacy of the intervention will be defined as a change from baseline value at 30 minutes and a change from baseline value at 4 weeks

    Measured: Immediately before intervention, after 30 minutes and after 4 weeks immediately after intervention

  3. Delayed visual recall

    The complex figure test will be used immediately before the intervention, repeated after 30 minutes and immediately after intervention after 4 weeks. The efficacy of the intervention will be defined as a change from baseline value at 30 minutes and a change from baseline value at 4 weeks.

    Measured: Immediately before intervention, at 30 minutes and immediately after intervention at 4 weeks

Secondary outcomes (3)
  1. Mood

    The Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) for evaluation of depression will be used. The change from baseline value at 8 and 16 weeks will be assessed

    Measured: Immediately before and two times (immediately after the intervention and 8 weeks later).

  2. Anxiety

    Generalized anxiety disorder (GAD) inventory for evaluation of anxiety will be used two times - before and after interventions (after 8 and 16 weeks). The change from baseline value at 8 and 16 weeks will be assessed

    Measured: Immediately before and after intervention.

  3. Stigma

    Jacoby's 3-item Stigma Scale will be used two times - before and after interventions (after 8 and 16 weeks). The change from baseline value at 8 and 16 weeks will be assessed.

    Measured: Immediately before and after intervention.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Jul 2023
  2. Study start11 Oct 2023
  3. Primary completionNov 2025 (estimated)
  4. Study completionNov 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Crossover
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
70 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05934786
Sponsor's protocol ID
ReCaP-ABLE-1
Acronym
ReCaPABLE
Status last verified
Sep 2025
First submitted
15 Jun 2023
Last updated
23 Sep 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Puteikis K, Jakoniene A, Jasionis A, Wolf P, Mameniskiene R. Rehabilitation of cognition and psychosocial well-being - a better life with epilepsy (ReCaP-ABLE): a protocol for a randomized waitlist-controlled trial. Front Neurol. 2023 Oct 27;14:1273550. doi: 10.3389/fneur.2023.1273550. eCollection 2023.

    PubMed 37965169

Questions about this trial

What is this clinical trial studying?

A study testing Cognitive rehabilitation in people with Epilepsy, run by Vilnius University at 1 site in Lithuania.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 23 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Lithuania. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Quality of life index (time frame: Immediately before intervention and after.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05934786, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in